United Therapeutics Corporation
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving United Therapeutics Corporation now
Current reporting with the operating signal separated from the noise.
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
The story matters when it changes United Therapeutics Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
The story matters when it changes United Therapeutics Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
The story matters when it changes United Therapeutics Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
The story matters when it changes United Therapeutics Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
The story matters when it changes United Therapeutics Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive ...
The story matters when it changes United Therapeutics Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension Transcript
The story matters when it changes United Therapeutics Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
The story matters when it changes United Therapeutics Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest UTHR filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
United Therapeutics Corporation, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →